IQVIA Holdings Inc. (IQV)
IQVIA Holdings (IQV) Q1 Earnings and Revenues Beat Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago.
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain IQV Stock in Your Portfolio Now
IQVIA's AI push with NVIDIA, strategic deals and buybacks drive growth, but weakening liquidity raises concerns over near-term financial flexibility.
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA Holdings Inc. $IQV Stock Holdings Lifted by Broyhill Asset Management LLC
Broyhill Asset Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,010 shares of the medical research company's stock after buying an additional 3,560 shares during the
IQVIA Holdings Inc. $IQV Shares Sold by Glenmede Investment Management LP
Glenmede Investment Management LP reduced its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 8.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,711 shares of the medical research company's stock after selling 19,677 shares during
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript
IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript
IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder
IQVIA Holdings delivered strong Q4 and full-year 2025 results, confirming its leadership in data, analytics, and clinical execution. Despite macro headwinds and cautious biotech spending, IQV maintained robust profitability, near-100% cash conversion, and expanded its $32.7B backlog. EPS guidance for 2026 was below consensus, triggering a selloff, but I remain bullish due to durable bookings, backlog, and elite financial metrics.
IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Is the Options Market Predicting a Spike in IQVIA Stock?
Investors need to pay close attention to IQVIA stock based on the movements in the options market lately.
